Abstract
Exon skipping induced by gene mutations is a common mechanism responsible for many genetic diseases. A practical approach to correct the aberrant splicing of defective genes is to use antisense oligonucleotides (ASOs). The recognition of splice sites and the regulation of splicing involve multiple positive or negative cis-acting elements and trans-acting factors. Base-pairing of ASOs to a negative element in a targeted pre-mRNA blocks the binding of splicing repressors to this cis-element and/or disrupts an unfavorable secondary structure; as a result, the ASO restores exon inclusion. For example, we have recently shown that appropriate 2′-O-(2-methoxyethyl) (MOE) phosphorothioate-modified ASOs can efficiently correct survival motor neuron 2 (SMN2) exon 7 splicing in a cell-free splicing assay, in cultured human cells—including patient fibroblasts—and in both peripheral tissues and the CNS of SMA mouse models. These ASOs are promising drug leads for SMA therapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigo R (2005) FEBS Lett 579:1900–1903
Anderson SL, Coli R, Daly IW, Kichula EA, Rork MJ, Volpi SA, Ekstein J, Rubin BY (2001) Am J Hum Genet 68:753–758
Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, Scherf M, Seifert M, Borodina T, Soldatov A, Parkhomchuk D, Schmidt D, O’Keeffe S, Haas S, Vingron M, Lehrach H, Yaspo ML (2008) Science 321:956–960
Sazani P, Gemignani F, Kang SH, Maier MA, Manoharan M, Persmark M, Bortner D, Kole R (2002) Nat Biotechnol 20:1228–1233
Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR (2007) PLoS Biol 5:e73
Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR (2008) Am J Hum Genet 82:834–848
Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, Krainer AR (2010) Genes Dev 24:1634–1644
Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M et al (1995) Cell 80:155–165
Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) Proc Natl Acad Sci USA 96:6307–6311
Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, McPherson JD (1999) Hum Mol Genet 8:1177–1183
Cartegni L, Krainer AR (2002) Nat Genet 30:377–384
Kashima T, Manley JL (2003) Nat Genet 34:460–463
Mayeda A, Krainer AR (1999) Methods Mol Biol 118:315–321
Mayeda A, Krainer AR (1999) Methods Mol Biol 118:309–314
Mattis VB, Butchbach ME, Lorson CL (2008) J Neurosci Methods 175:36–43
Saito T (2006) Nat Protoc 1:1552–1558
Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, Lobsiger CS, Ward CM, McAlonis-Downes M, Wei H, Wancewicz EV, Bennett CF, Cleveland DW (2006) J Clin Invest 116:2290–2296
Acknowledgments
The authors thank Drs C. Frank Bennett, Timothy A. Vickers, Brenda F. Baker, Gene Hung, and Frank Rigo at Isis Pharmaceuticals for providing MOE ASOs, for many helpful discussions, and sharing protocols, as well as Dr. Kentaro Sahashi at Cold Spring Harbor Laboratory for helping to implement the embryonic ICV injection procedure. The relevant research in the authors’ laboratory was generously supported by the Muscular Dystrophy Association, the National Institute of Neurological Disorders and Stroke, and the SMA Foundation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Hua, Y., Krainer, A.R. (2012). Antisense-Mediated Exon Inclusion. In: Aartsma-Rus, A. (eds) Exon Skipping. Methods in Molecular Biology, vol 867. Humana Press. https://doi.org/10.1007/978-1-61779-767-5_20
Download citation
DOI: https://doi.org/10.1007/978-1-61779-767-5_20
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-766-8
Online ISBN: 978-1-61779-767-5
eBook Packages: Springer Protocols